Motley Fool Asset Management LLC Purchases 198 Shares of ResMed Inc. (NYSE:RMD)

Motley Fool Asset Management LLC raised its position in shares of ResMed Inc. (NYSE:RMD) by 4.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,397 shares of the medical equipment provider’s stock after acquiring an additional 198 shares during the period. Motley Fool Asset Management LLC’s holdings in ResMed were worth $756,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also bought and sold shares of the company. EverSource Wealth Advisors LLC boosted its stake in shares of ResMed by 224.6% during the third quarter. EverSource Wealth Advisors LLC now owns 185 shares of the medical equipment provider’s stock valued at $27,000 after purchasing an additional 128 shares during the period. Operose Advisors LLC purchased a new stake in ResMed in the third quarter worth about $32,000. Planned Solutions Inc. purchased a new stake in ResMed in the fourth quarter worth about $34,000. MV Capital Management Inc. lifted its stake in ResMed by 39.0% in the fourth quarter. MV Capital Management Inc. now owns 214 shares of the medical equipment provider’s stock worth $37,000 after acquiring an additional 60 shares during the period. Finally, Turtle Creek Wealth Advisors LLC purchased a new stake in ResMed in the fourth quarter worth about $45,000. Institutional investors own 54.98% of the company’s stock.

ResMed Stock Up 18.9 %

Shares of RMD traded up $34.64 during mid-day trading on Friday, hitting $218.06. 4,330,318 shares of the company traded hands, compared to its average volume of 1,056,215. ResMed Inc. has a 1-year low of $132.24 and a 1-year high of $243.52. The business has a 50 day moving average of $187.07 and a 200 day moving average of $171.97. The company has a quick ratio of 1.89, a current ratio of 3.11 and a debt-to-equity ratio of 0.27. The company has a market capitalization of $32.07 billion, a PE ratio of 36.04, a price-to-earnings-growth ratio of 2.25 and a beta of 0.67.

ResMed (NYSE:RMD) last issued its quarterly earnings results on Thursday, April 25th. The medical equipment provider reported $2.13 earnings per share for the quarter, topping the consensus estimate of $1.91 by $0.22. ResMed had a net margin of 19.77% and a return on equity of 23.86%. The company had revenue of $1.20 billion for the quarter, compared to the consensus estimate of $1.17 billion. During the same quarter in the prior year, the company earned $1.68 EPS. ResMed’s quarterly revenue was up 7.2% on a year-over-year basis. Equities research analysts anticipate that ResMed Inc. will post 7.47 EPS for the current year.

Insider Buying and Selling

In related news, Director Peter C. Farrell sold 10,935 shares of the stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $182.66, for a total value of $1,997,387.10. Following the transaction, the director now owns 157,404 shares in the company, valued at approximately $28,751,414.64. The sale was disclosed in a filing with the SEC, which is available through this link. In other ResMed news, General Counsel Michael J. Rider sold 200 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $173.25, for a total value of $34,650.00. Following the sale, the general counsel now owns 6,688 shares in the company, valued at approximately $1,158,696. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Peter C. Farrell sold 10,935 shares of the company’s stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $182.66, for a total value of $1,997,387.10. Following the completion of the sale, the director now owns 157,404 shares in the company, valued at approximately $28,751,414.64. The disclosure for this sale can be found here. In the last quarter, insiders have sold 11,216 shares of company stock worth $2,046,617. 1.21% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of research firms recently weighed in on RMD. JPMorgan Chase & Co. upped their price objective on shares of ResMed from $160.00 to $195.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 9th. Mizuho reiterated a “buy” rating and issued a $215.00 target price on shares of ResMed in a report on Wednesday, March 27th. KeyCorp boosted their target price on shares of ResMed from $227.00 to $238.00 and gave the stock an “overweight” rating in a report on Friday. Royal Bank of Canada boosted their target price on shares of ResMed from $187.00 to $200.00 and gave the stock a “sector perform” rating in a report on Friday. Finally, UBS Group boosted their target price on shares of ResMed from $175.00 to $180.00 and gave the stock a “neutral” rating in a report on Thursday, January 25th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, ResMed has an average rating of “Moderate Buy” and a consensus target price of $202.80.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.